Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Stock Short Interest Drops 63.0%

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report) saw a significant drop in short interest in October. As of October 30th, there was short interest totaling 5,139 shares, a drop of 63.0% from the October 15th total of 13,889 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 48,290 shares, the short-interest ratio is presently 0.1 days.

Chemomab Therapeutics Price Performance

Shares of Chemomab Therapeutics stock traded up $0.10 during trading hours on Monday, reaching $1.62. The company’s stock had a trading volume of 23,752 shares, compared to its average volume of 93,814. The firm has a 50 day moving average price of $1.65 and a 200-day moving average price of $1.74. Chemomab Therapeutics has a one year low of $0.92 and a one year high of $2.99. The stock has a market cap of $11.77 million, a P/E ratio of -0.76 and a beta of 0.80.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.12).

Wall Street Analyst Weigh In

CMMB has been the topic of a number of research reports. Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 3rd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Chemomab Therapeutics has a consensus rating of “Reduce”.

Read Our Latest Analysis on CMMB

About Chemomab Therapeutics

(Get Free Report)

Chemomab Therapeutics is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring. The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis. Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics.

Further Reading

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.